According to filings with the U.S. Securities and Exchange Commission, Entopsis is raising $6,000,000.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, George Huang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Entopsis
We are a young and driven biotech startup team based in Miami, Florida. Our aim is to create a cost-effective platform for regular health monitoring. Entopsis utilizes a proprietary material science screening platform to develop cost-effective and impactful products. Our leading solutions: 1) OpsisDx: universal platform to diagnose cancer and various diseases thru urine www.entopsis.com 2) PCRopsis: series of time & cost saving technologies for the life sciences www.PCRopsis.com. Entopsis was founded in 2011 to pursue the simple idea that an unbiased approach to diagnostics using signatures can be clinically and scientifically useful. We are predominantly focused in the ares of oncology, autoimmune disorders, and rare diseases. Entopsis is proud to have established strategic academic and industry collaborations with renowned companies and institutions.

To learn more about Entopsis, visit http://entopsis.com/

Contact:
George Huang, Chief Financial Officer
888-407-5070
https://www.linkedin.com/in/george-huang-61136b1a9/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.